Child Vaccination Programme — Cost, Top Hospitals & Success Rates | MyMedicPlus

Child vaccination (immunisation) is the administration of biological preparations — vaccines — that stimulate the immune system to produce protective antibodies against specific infectious diseases without causing the disease itself. Vaccination is one of the most successful and cost-effective public health interventions in history, preventing an estimated 4–5 million deaths annually and having eradicated smallpox and near-eliminated polio globally. Vaccines work through four main mechanisms: live-attenuated vaccines (containing weakened live organisms — MMR, chickenpox, rotavirus, BCG) produce the strongest and most durable immunity but require an intact immune system; inactivated vaccines (killed organisms — IPV, influenza, hepatitis A) are safe in immunocompromised individuals; subunit, recombinant, or conjugate vaccines (specific protein antigens — hepatitis B, Hib, pneumococcal, meningococcal, HPV) target highly immunogenic proteins; and mRNA vaccines (COVID-19) use genetic instructions to produce the target protein. The WHO Expanded Programme on Immunisation (EPI) provides a core schedule; national programmes augment this with country-specific vaccines. India's Universal Immunisation Programme (UIP) covers 12 diseases; international travel vaccines may add typhoid, hepatitis A, yellow fever, Japanese encephalitis, and others. Booster doses maintain immunity as maternal antibody protection wanes and immunological memory requires reinforcement. The childhood immunisation schedule is designed to provide protection at the earliest age when risk is highest and the immune response is adequate.

The standard childhood vaccination schedule prevents: tuberculosis (BCG vaccine — protects against severe TB meningitis and miliary TB in children); hepatitis B (birth dose and 2 boosters — prevents chronic liver disease and hepatocellular carcinoma); poliomyelitis (oral polio vaccine OPV plus inactivated IPV — prevents paralytic polio); diphtheria, tetanus, pertussis (DTwP/DTaP — prevents the 'DTP' triad of serious bacterial infections); Haemophilus influenzae type b (Hib — prevents Hib meningitis, pneumonia, and epiglottitis); pneumococcal disease (PCV13/PCV15/PCV20 — prevents pneumococcal pneumonia and meningitis); rotavirus gastroenteritis (RV vaccine — the leading cause of severe diarrhoeal dehydration in children under 5); measles, mumps, rubella (MMR — prevents measles encephalitis, mumps orchitis/infertility, and congenital rubella syndrome); varicella/chickenpox; hepatitis A; typhoid fever; meningococcal meningitis; human papillomavirus (HPV — prevents cervical cancer and anogenital warts); influenza; and Japanese encephalitis in endemic areas. India's UIP includes BCG, OPV, IPV, DPT, hepatitis B, Hib (Pentavalent), PCV, rotavirus, MMR, JE, DT, TT, and TD vaccines.

All healthy children from birth through adolescence should follow the national immunisation schedule. India's UIP schedule begins at birth (BCG, OPV0, Hep B birth dose), with vaccines at 6 weeks, 10 weeks, 14 weeks, 9 months, 12 months, 16–24 months, 5 years, 10 years, and 16 years. Most children are eligible for all standard vaccines. Immunocompromised children (primary immunodeficiency, HIV, cancer treatment, organ transplant, long-term steroids) require special consideration: live vaccines (MMR, BCG, chickenpox, rotavirus) are generally contraindicated; inactivated vaccines are safe and should be prioritised. Premature infants receive vaccines according to chronological age (not corrected age) with the exception of hepatitis B birth dose, which may be deferred in very low birth weight infants. Mild illness (common cold, low-grade fever) is not a contraindication for vaccination. Previous severe allergic reaction (anaphylaxis) to a vaccine component is the primary contraindication. Catch-up schedules are available for children who missed vaccines. International travellers may require additional vaccines (typhoid, hepatitis A, yellow fever, meningococcal) based on destination.

Childhood immunisation provides individual protection, herd immunity, and elimination of disease. Individual benefit: vaccinated children are protected against potentially fatal or severely disabling diseases; measles vaccine prevents encephalitis (1 in 1,000 cases) and death; Hib vaccine has reduced Hib meningitis by 99% in countries with universal coverage; rotavirus vaccine reduces severe gastroenteritis hospitalisations by 50–80%; PCV has reduced invasive pneumococcal disease by 70–80%; HBV vaccine prevents chronic hepatitis leading to cirrhosis and liver cancer decades later. Herd immunity: when 90–95% of a community is immunised, disease transmission is broken, protecting those who cannot be vaccinated (newborns, immunocompromised). Disease elimination: measles, mumps, rubella, polio, diphtheria, and Hib meningitis have been virtually eliminated in countries with high vaccine coverage. Economic benefit: vaccination prevents massive healthcare costs from treating vaccine-preventable diseases and reduces lost productivity. HPV vaccination of adolescents prevents cervical cancer — the second most common cancer in women globally — by over 90% when given before first sexual exposure.

Vaccines are among the safest medical interventions available. Common, mild, and transient side effects include: pain, redness, and swelling at the injection site (10–30%); low-grade fever (5–15%); irritability and crying in infants (up to 60% after DTwP); temporary drowsiness; and mild rash 7–14 days after MMR or chickenpox vaccine. These reactions are signs of immune system activation and resolve within 1–3 days. Serious adverse events are rare: febrile seizure after MMR (1 in 3,000) — brief, self-limiting, and not associated with long-term consequences; severe allergic reaction (anaphylaxis) — approximately 1 in 1,000,000 vaccine doses, managed with epinephrine at vaccination sites. The claim that MMR vaccine causes autism has been comprehensively disproved by over 20 large-scale studies involving millions of children; the original 1998 Wakefield paper was retracted and the author struck off the medical register for fraud. Vaccine-preventable diseases kill and disable far more children than any vaccine side effects. All nationally approved vaccines undergo rigorous safety testing before approval and are subject to ongoing pharmacovigilance.

In India, all vaccines in the Universal Immunisation Programme (UIP) — BCG, OPV, IPV, DPT, hepatitis B, Pentavalent, PCV, rotavirus, MMR, MR, JE, and DT/TT — are provided free of charge at government health centres, anganwadis, and during outreach sessions nationwide. Private hospital vaccination costs for the complete schedule (including additional recommended vaccines like varicella, hepatitis A, typhoid, meningococcal, HPV) range from USD 200–500 for the entire childhood schedule from birth to adolescence. Premium combination vaccines (e.g., 6-in-1 hexavalent vaccine) cost USD 15–35 per dose privately. HPV vaccine (3 doses) costs USD 80–120 privately in India; it is free in the government programme for girls aged 9–14. In the USA, the complete childhood vaccine schedule costs USD 400–800 without insurance; with insurance most vaccines are covered fully. In the UK, all childhood vaccines are provided free by the NHS. Medical tourists to India often update their children's vaccines at private clinics — achieving international-standard vaccines at very affordable prices.

Childhood vaccination follows National Immunisation Programmes (NIPs) with core universal vaccines and additional vaccines for high-risk groups:

• Core universal vaccines (examples from UK NIP): BCG at birth for TB high-risk groups; Rotavirus oral vaccine at 8 and 12 weeks; DTaP/IPV/Hib/HepB (6-in-1 Infanrix Hexa) at 8, 12, 16 weeks; MenB (Bexsero) at 8, 16 weeks and 1 year; PCV13 at 12 weeks and 1 year; Hib/MenC booster at 1 year; MMR (Priorix) at 12 months and 3 years 4 months; MenACWY at 14–18 years; HPV (Gardasil 9) at 11–13 years; annual influenza (nasal spray Fluenz for under-18s).
• Vaccine types and mechanisms: Live attenuated vaccines (MMR, varicella, BCG, nasal flu, rotavirus) — weakened pathogens stimulate strong, durable cellular and humoral immunity; generally provide lifelong protection with 1–2 doses. Inactivated vaccines (IPV, hepatitis A, inactivated flu) — killed whole organisms; safe in immunocompromised but require multiple doses and boosters. Subunit/protein vaccines (pertussis, MenB Bexsero, HPV Gardasil) — purified antigens; no live virus risk. Conjugate vaccines (PCV, Hib, MenACWY) — polysaccharide conjugated to carrier protein enabling immune response in infants under 2 years. mRNA vaccines (COVID-19) — synthetic mRNA encoding spike protein, delivered in lipid nanoparticles.
• Catch-up vaccination: Children who missed scheduled vaccines receive accelerated catch-up schedules — minimum intervals between doses (typically 4 weeks minimum between primary doses) allow faster completion. MMR can be given at any age; DTaP catch-up series by age 7 then Tdap for older children. NHS, CDC, and WHO provide age-specific catch-up schedules.
• High-risk additional vaccines: Hepatitis B for all newborns in 90% of countries globally; varicella (chickenpox) on USA and many schedules; hepatitis A for travel/endemic exposure; rabies, yellow fever, typhoid for travel; pneumococcal and influenza for immunocompromised, cardiac or pulmonary disease.

Vaccination follow-up focuses on reaction monitoring and ensuring schedule completion:

• Immediate post-vaccination (15–30 minutes): Observe for immediate hypersensitivity — anaphylaxis (incidence ~1.3 per million doses) presents within minutes with urticaria, angioedema, wheeze, and hypotension. Pre-filled adrenaline (0.3 mg IM) and resuscitation equipment must be available at all vaccination sites.
• Expected local reactions (parent education): Injection site redness, swelling, and tenderness lasting 1–3 days — normal, managed with cool compress and paracetamol or ibuprofen. Fever within 24–48 hours (particularly after MenB) — give prophylactic paracetamol post-MenB. MMR-related mild rash or low fever at 7–12 days — vaccine virus replication, not contagious.
• Vaccination record maintenance: UK red book, US immunisation records, or digital NIP registry. Records should be presented at every healthcare encounter and checked at school entry, school nurse assessments, and travel health consultations.
• Schedule completion review: Missed vaccines identified at 1-year, pre-school (4–5 years), and school health entry reviews. HPV course completion verified at secondary school. Catch-up offered promptly via GP, school health team, or pharmacy.

Vaccination is the most effective preventive health intervention available. Alternatives to vaccination are very limited and generally inferior:

• Natural immunity: Infection with pathogens (measles, chickenpox, hepatitis A) confers lasting immunity but at the cost of disease complications — measles encephalitis (1 in 1,000 cases), subacute sclerosing panencephalitis (1 in 10,000), chickenpox bacterial superinfection, hepatitis A fulminant liver failure. Natural infection is not an acceptable substitute for safe, effective vaccines.
• Passive immunisation (immunoglobulins): Specific immunoglobulins (varicella-zoster immunoglobulin, hepatitis B immunoglobulin, rabies immunoglobulin) provide immediate short-term protection after exposure. Used alongside active vaccination in post-exposure protocols (hepatitis B at birth, rabies prophylaxis). Not suitable for routine vaccination.
• Vaccine deferral for medical contraindications: True medical contraindications are rare: anaphylaxis to a prior vaccine dose or specific component; live vaccines contraindicated in severely immunocompromised patients (primary immunodeficiency, active chemotherapy, solid organ transplant with high-dose immunosuppression); pregnancy is a contraindication for live vaccines. Most common reasons cited for vaccine refusal — autism (refuted by extensive evidence), egg allergy (not a contraindication for MMR or flu vaccine at recommended protocols), or mild current illness — are not genuine contraindications.